



The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

901.HEALTH SERVICES AND QUALITY IMPROVEMENT - NON-MALIGNANT CONDITIONS

Assessing Pain Severity in Sickle Cell Disease Using Animations and a Graphical Body Image

Julia A. O'Brien, PhD¹, Charles R. Jonassaint, PhD MHS², Christina M. Lalama, MS², Sherif M. Badawy, MD MBA, MS³, Megan E. Hamm, PhD², Jennifer Stinson, PhD CPNP, RN⁴, Chitra Laloo, PhD^{5,6}, Christopher Patrick Carroll, MD⁷, Santosh L. Saraf, MD⁸, Victor R. Gordeuk, MD^{9,10}, Robert Cronin, MDMS¹¹, Nirmish Shah, MD¹², Sophie Lanzkron, MD¹³, Darla K. Liles, MD¹⁴, Leshana Saint-Jean, PhD¹⁵, Michael R. DeBaun, MD MPH¹⁶, Cassandra Trimnell, BA¹⁷, Lakiea Bailey, PhD¹⁸, Raymona Holloway Lawrence, PhD MPH¹⁹, Laura M. Decastro, MD², Tonya Palermo, PhD²⁰, Kaleab Abebe, PhD²

¹ School of Nursing, University of Pittsburgh, Pittsburgh, PA

² Department of Medicine, University of Pittsburgh, Pittsburgh, PA

³ Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL

⁴ Child Health Evaluative Sciences in Research Institute, Hospital For Sick Children, Toronto, CAN

⁵ Institute for Health Policy, Management & Evaluation, University of Toronto, Toronto, Canada

⁶ Child Health Evaluation Sciences, Hospital for Sick Children, Toronto, Canada

⁷ School of Medicine, Johns Hopkins University, Baltimore, MD

⁸ Department of Medicine, University of Illinois College of Medicine, Willowbrook, IL

⁹ Department of Medicine, University of Illinois Chicago, Chicago, IL

¹⁰ Sickle Cell Center, University of Illinois at Chicago, Chicago, IL

¹¹ Department of Internal Medicine, The Ohio State University, Columbus, OH

¹² Department of Medicine, Division of Hematology - Duke Sickle Cell Comprehensive Care Unit, Duke University Medical Center, Cary, NC

¹³ Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD

¹⁴ Division of Hematology-Oncology, Department of Internal Medicine, East Carolina University Brody School of Medicine, Greenville, NC

¹⁵ Vanderbilt University, Nashville, TN

¹⁶ Vanderbilt University School of Medicine, Nashville, TN

¹⁷ Sickle Cell 101, San Francisco, CA

¹⁸ Sickle Cell Community Consortium, Atlanta, GA

¹⁹ Jiann Ping Hsu College of Public Health, Georgia Southern University, Statesboro, GA

²⁰ Department of Anesthesiology & Pain Medicine, University of Washington, Seattle, WA

Introduction: Adults living with sickle cell disease (SCD) most frequently seek medical care due to pain. To determine the most efficacious treatment plan for patients presenting with pain, providers must first accurately assess and diagnose the pain. Unfortunately, the current approaches for assessing pain are inadequate. Combined with medical provider biases, patients can often have their pain symptoms misinterpreted, ignored, or blatantly dismissed. To address this issue, we partnered with stakeholders, human-centered designers, and software engineers to design a novel pain assessment tool, called Painimation. Painimation allows patients to communicate their pain quality, intensity, and location using abstract animations and a paintable body image. Painimation has been validated in a general population with chronic pain, but there is limited data validating this approach in SCD. Preliminary data on the use of Painimation by adults with SCD (N = 67) found that those who described their pain using the "throbbing" animation had less severe pain symptoms than those endorsing the "shooting" animation. **Objective:** To replicate and extend prior findings by determining whether pain animations and body image data are associated with pain outcomes in a large cohort of adults with SCD. We hypothesized that the presence of shooting pain and greater body surface areas affected by pain would be associated with more severe pain outcomes and mental health symptoms. **Methods:** We performed a secondary analysis on baseline data from the "Cognitive Behavioral Therapy and Real-Time Pain Management Intervention for Sickle Cell via Mobile Application (CaRISMA)" Trial-a multisite randomized, controlled trial in adults with SCD and chronic pain. Eligible patients were randomized 1:1 to either digital cognitive behavioral therapy or digital

education; in addition, both arms received at least 12 weeks of health coach support. At baseline, participants completed a battery of questionnaires and tracked their pain intensity (0-10) by the Visual Analog Scale (VAS) and mood daily via a mobile app. The Painimation app presents a front and back 2-dimensional body image that is paintable to indicate areas affected by pain. Users choose from abstract animations intended to represent different pain qualities; the intensity of the animations can be adjusted, and up to three can be selected. For the purpose of the analyses, participants were categorized into "Shooting Pain" vs "No Shooting Pain" and "Throbbing with Shooting and Stabbing" vs "Throbbing Alone," based on our prior study. Participants were also split into groups based on whether the proportion of the body image painted was less than the median ($<9.8\%$ vs $\geq 9.8\%$). Baseline characteristics and demographics were compared between groups, and multivariable regressions were used to estimate covariate-adjusted associations with the following outcomes at baseline: daily pain, Patient Reported Outcomes Measurement Information System (PROMIS) pain interference scale, Pain Catastrophizing Scale (PCS), Current Opioid Misuse Measure (COMM-9), and Adults Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) pain severity and frequency.

Results: The trial enrolled 359 adults, mean age 36.3 (SD = 10.5), 66% female, 93% Black race. The "Shooting" painimation and greater body image scores were associated with all outcomes in univariate analyses (all $p < 0.01$; Table 1) except for the proportion of "happy" mood days and anxiety scores. After controlling for age, depression, anxiety, % body image, and site, the shooting animations were independently associated with greater daily pain intensity (beta = 0.64; $p = 0.046$). After controlling for age, depression, and site, greater body image score was associated with daily pain intensity (beta = 1.18; $p < 0.001$), pain interference (beta = 2.87; $p < 0.001$), ASCQ-Me pain frequency (beta = 3.91; $p < 0.005$), and ASCQ-Me pain severity (beta = 4.50; $p = 0.002$).

Conclusion: Both the "shooting" animation and body image measures were associated with more severe pain outcomes. This study demonstrates that animations and body image data can be used to assess pain severity in SCD, more objectively than the 0-10 numeric VAS scale. Future studies should explore whether pain location and specific animation selected are associated with pain etiology, and determine whether this approach can differentiate different types of pain in SCD.

Disclosures O'Brien: Johnson & Johnson: Current equity holder in publicly-traded company; Lilly Eli & Co: Current equity holder in publicly-traded company; Pfizer: Current equity holder in publicly-traded company; 3M Co.: Current equity holder in publicly-traded company; Embecta: Current equity holder in publicly-traded company; Colgate-Palmolive: Current equity holder in publicly-traded company; Becton Dickinson: Current equity holder in publicly-traded company; Ashland Inc: Current equity holder in publicly-traded company; AbbVie Inc: Current equity holder in publicly-traded company.

Jonassaint: Expressive Painimation: Current Employment, Current equity holder in private company; Agios: Consultancy, Honoraria. **Badawy:** Bluebird bio, INC: Consultancy; Chiesi, Inc: Consultancy; Vertex Pharmaceuticals Inc: Consultancy; Editas Medicine: Consultancy; Bristol-Myers Squibb: Consultancy; Forma Therapeutics/Novo Nordisk: Consultancy; GBT/Pfizer: Consultancy. **Saraf:** BEAM Therapeutics: Consultancy, Other: Advisory board; Novartis: Consultancy, Other: Advisory board, Research Funding; GBT/Pfizer: Consultancy, Other: Advisory board, Research Funding, Speakers Bureau; Forma Therapeutics: Consultancy, Other: Advisory board, Research Funding; Agios: Consultancy, Other: Advisory board. **Gordeuk:** Emmaus: Consultancy, Research Funding; GBT/Pfizer: Consultancy, Research Funding; Takeda: Consultancy; CSL-Behring: Consultancy; Novartis: Research Funding; Incyte: Research Funding; Forma: Consultancy, Research Funding; Modus Therapeutics: Consultancy. **Shah:** Agios Pharmaceuticals: Consultancy; Global Blood Therapeutics/Pfizer: Consultancy, Research Funding, Speakers Bureau; Alexion Pharmaceuticals: Speakers Bureau; Vertex: Consultancy; Bluebird bio: Consultancy; Forma: Consultancy.

Lanzkron: Teva Pharmaceutical Industries: Current equity holder in publicly-traded company; Imara/Enliven Therapeutics: Research Funding; Magenta: Consultancy; Novo Nordisk: Consultancy; Pfizer: Consultancy; HRSA: Research Funding; PCORI: Research Funding; Bluebird Bio: Consultancy; CSL-Behring: Research Funding; Global Blood Therapeutics: Research Funding; Takeda: Research Funding; National Alliance for Sickle Cell Centers: Other: Vice president ; Novartis: Consultancy, Research Funding. **Liles:** Alpine Immune Sciences: Other: Clinical trial activity (Principal investigator or sub-investigator); Annexon Biosciences: Other: Clinical trial activity (Principal investigator or sub-investigator); Abbvie: Other: Clinical trial activity (Principal investigator or sub-investigator); Astex Pharmaceuticals: Other: Clinical trial activity (Principal investigator or sub-investigator); Baxalta: Other: Clinical trial activity (Principal investigator or sub-investigator); BeiGene: Other: Clinical trial activity (Principal investigator or sub-investigator); Bioverativ: Other: Clinical trial activity (Principal investigator or sub-investigator); CSL Behring: Other: Clinical trial activity (Principal investigator or sub-investigator); Celgene: Other: Clinical trial activity (Principal investigator or sub-investigator); Delta-Fly Pharma: Other: Clinical trial activity (Principal investigator or sub-investigator); Exact Sciences: Other: Clinical trial activity (Principal investigator or sub-investigator); Forma Therapeutics: Other: Clinical trial activity (Principal investigator or sub-investigator); Global Blood Therapeutics: Other: Clinical trial activity (Principal investigator or sub-investigator); Immunovant: Other: Clinical trial activity (Principal investigator or sub-investigator); Incyte: Other: Clinical trial activity (Principal investigator or sub-investigator); Janssen Pharmaceuticals: Other: Clinical trial activity (Principal investigator or sub-investigator); NeolImmuneTech: Other: Clinical trial activity (Principal investigator or sub-investigator); Novartis: Other: Clinical trial activity (Principal investigator or sub-investigator); Novo Nordisk: Other: Clinical trial activity (Principal investigator or sub-investigator); Partner Therapeutics: Other: Clinical trial activity (Principal investigator or sub-investigator); Pharm-Olam: Other: Clinical trial activity (Principal investigator or sub-investigator); Principia Biopharma: Other: Clinical trial activity (Principal investigator or sub-investigator); Salix Pharmaceuticals: Other: Clinical trial activity (Principal investigator or sub-investigator); Sanofi-Aventis: Other: Clinical trial activity (Principal investigator or sub-investigator); Takeda: Other: Clinical trial activity (Principal investigator or sub-investigator); Vifor Pharma: Other: Clinical trial activity (Principal in-

vestigator or sub-investigator). **DeBaun:** *FORMA*: Consultancy; *Vertex/CRISPR*: Membership on an entity's Board of Directors or advisory committees; *Novartis Pharmaceuticals Corporation*: Other: Study steering committee member; *Global Blood Therapeutics*: Membership on an entity's Board of Directors or advisory committees, Research Funding. **Trimnell:** *Agios Pharmaceuticals*: Consultancy; *Novo Nordisk*: Consultancy; *Pfizer*: Consultancy, Honoraria; *Bluebird bio*: Honoraria; *Graphite Bio*: Consultancy; *Novartis*: Consultancy; *Vertex*: Honoraria. **Decastro:** *Forma Therapeutics*: Other: Advisory board; *Global Blood Therapeutics*: Other: Advisory board; *GlycoMimetics*: Other: Advisory board; *Novartis*: Other: Advisory board.

<https://doi.org/10.1182/blood-2023-189667>

Table 1. Pain and psychosocial outcomes by selection of "shooting" pain among adults with SCD and chronic pain

	No Shooting Pain (N=213)	Shooting Pain (N=146)	P-value
# of Diary Entries, 2 Weeks			
Mean (SD) [Min, Max]	8.88 (4.14) [1.00, 14.0]	8.41 (4.07) [1.00, 14.0]	0.34
Missing	37 (17.4%)	23 (15.8%)	
Avg Pain VAS (0-10), Daily Diary			
Mean (SD) [Min, Max]	3.94 (2.46) [0, 8.80]	4.99 (2.48) [0, 9.50]	<0.001
Missing	37 (17.4%)	23 (15.8%)	
Freq Happy Mood, Daily Diary			
Mean (SD) [Min, Max]	0.105 (0.162) [0, 0.769]	0.122 (0.197) [0, 1.00]	0.444
Missing	37 (17.4%)	23 (15.8%)	
PROMIS Pain Interference			
Mean (SD) [Min, Max]	61.2 (7.79) [40.7, 77.0]	64.5 (5.46) [51.2, 77.0]	<0.001
ASCQ-Me			
Pain Frequency			
Mean (SD) [Min, Max]	46.0 (13.2) [20.8, 63.5]	51.5 (10.1) [20.8, 63.5]	<0.001
Pain Severity			
Mean (SD) [Min, Max]	44.7 (14.4) [14.9, 66.3]	51.1 (10.4) [14.9, 66.3]	<0.001
Social Functioning			
Mean (SD) [Min, Max]	48.8 (7.84) [26.0, 69.8]	45.1 (7.44) [26.0, 69.8]	<0.001
Emotional Impact			
Mean (SD) [Min, Max]	49.3 (8.91) [26.8, 65.6]	46.2 (8.41) [26.8, 65.6]	0.0010
PHQ-9 Depressive Symptoms			
Mean (SD) [Min, Max]	9.45 (4.84) [1.00, 24.0]	11.3 (5.23) [2.00, 27.0]	0.0025
Missing	44 (20.7%)	23 (15.8%)	
GAD-7 Anxiety Symptoms			
Mean (SD) [Min, Max]	8.41 (4.48)	8.84 (4.67)	0.469
Median [Min, Max]	7.00 [2.00, 21.0]	8.00 [2.00, 21.0]	
Missing	78 (36.6%)	30 (20.5%)	
PCS Pain Catastrophizing			
Mean (SD) [Min, Max]	8.69 (4.20) [0, 16.0]	10.1 (3.86) [0, 16.0]	<0.001
COMM-9 Opioid Use Behaviors			
Mean (SD) [Min, Max]	8.18 (5.35) [0, 28.0]	9.84 (5.37) [0, 29.0]	0.0042
% Body Area in Pain			
Mean (SD) [Min, Max]	10.1 (12.4) [0, 84.0]	18.5 (17.0) [0.248, 93.3]	<0.001

Table 2. Pain and psychosocial outcomes by total body image (TBI) percentage among adults with SCD and chronic pain

	TBI < Median (9.8%) (N=191)	TBI ≥ Median (9.8%) (N=168)	P-value
# of Diary Entries, 2 Weeks			
Mean (SD) [Min, Max]	8.91 (4.04) [1.00, 14.0]	8.44 (4.19) [1.00, 14.0]	0.331
Missing	33 (17.3%)	27 (16.1%)	
Avg Pain VAS (0-10), Daily Diary			
Mean (SD) [Min, Max]	3.76 (2.54) [0, 9.43]	5.07 (2.32) [0, 9.50]	<0.001
Missing	33 (17.3%)	27 (16.1%)	
Freq Happy Mood, Daily Diary			
Mean (SD) [Min, Max]	0.133 (0.199) [0, 1.00]	0.0885 (0.146) [0, 0.889]	0.0267
Missing	33 (17.3%)	27 (16.1%)	
PROMIS Pain Interference			
Mean (SD) [Min, Max]	60.5 (7.41) [40.7, 77.0]	65.0 (5.93) [40.7, 77.0]	<0.001
ASCQ-Me			
Pain Frequency			
Mean (SD) [Min, Max]	45.8 (13.2) [20.8, 63.5]	51.1 (10.7) [20.8, 63.5]	<0.001
Pain Severity			
Mean (SD) [Min, Max]	44.4 (14.5) [14.9, 66.3]	50.5 (11.0) [14.9, 66.3]	<0.001
Social Functioning			
Mean (SD) [Min, Max]	49.3 (7.86) [29.8, 69.8]	45.0 (7.24) [26.0, 69.8]	<0.001
Emotional Impact			
Mean (SD) [Min, Max]	50.1 (8.76) [26.8, 65.6]	45.6 (8.29) [26.8, 65.6]	<0.001
PHQ-9 Depressive Symptoms			
Mean (SD) [Min, Max]	9.33 (4.84) [1.00, 23.0]	11.1 (5.18) [2.00, 27.0]	0.0028
Missing	47 (24.6%)	20 (11.9%)	
GAD-7 Anxiety Symptoms			
Mean (SD) [Min, Max]	7.78 (4.54) [2.00, 21.0]	9.41 (4.46) [2.00, 21.0]	0.0046
Missing	68 (35.6%)	40 (23.8%)	
PCS Pain Catastrophizing			
Mean (SD) [Min, Max]	8.53 (4.19) [0, 16.0]	10.1 (3.89) [0, 16.0]	<0.001
COMM-9 Opioid Use Behaviors			
Mean (SD) [Min, Max]	7.70 (4.98) [0, 25.0]	10.2 (5.60) [0, 29.0]	<0.001

Figure 1